Bioactive Products
| A unique collection of 267 Inhibitor natural compounds | ||
| Catalog No: | Bb221 | Inhibitors Compound Library Screening Details |
| Size: | 1mg/well * 267 Compounds 2mg/well * 267 Compounds | |
| Cat. No. | Information |
| CFN92402 | Alisol F Alisol F shows anti-inflammatory activities and liver protectionthrough the inhibition of MAPK, STAT3, and NF-κB activation in vitro and in vivo, it suppresses iNOS induction. Alisol F exhibits inhibitory activity in vitro on hepatitis B virus (HBV) surface antigen (HBsAg) secretion of the Hep G2.2.15 cell line with the IC (50) value of 0.6 microM, and on HBV e antigen (HBeAg) secretion with the IC (50) value of 8.5 microM. |
| CFN92403 | 25-Anhydroalisol F 25-Anhydroalisol F shows anti-inflammatory activities and liver protection through the inhibition of MAPK, STAT3, and NF-κB activation in vitro and in vivo. It exhibits inhibitory effects on lipopolysaccharide-induced NO production in RAW 264.7 macrophage cells. |
| CFN92406 | Alisol B Alisol B, a novel inhibitor of the sarcoplasmic/endoplasmic reticulum Ca(2+) ATPase pump, induces autophagy, endoplasmic reticulum stress, and apoptosis.Alisol B may be a potential novel therapeutic molecule for bone disorders through targeting the differentiation of osteoclasts as well as their functions. Alisol B also inhibited RANKL-induced expression of NFATc1 and c-Fos, which are key transcription factors for osteoclastogenesis. |
| CFN90503 | Ophiopogonin D' Ophiopogonin D' can activate SIRT1, it also noncompetitively inhibits UGT1A6 and UGT1A10. |
| CFN92431 | Kazinol A Kazinol A shows strong inhibition of arachidonic acid (AA)-induced platelet aggregation. It also exhibits potent inhibition with IC50 values ranging 0.6–164 M against XOD. Kazinol A may be a candidate for the development of effective anti-cancer drug on human urinary bladder cancer, it induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2. |
